These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 21052642)

  • 1. Oral bisphosphonates are associated with reduced mortality after hip fracture.
    Beaupre LA; Morrish DW; Hanley DA; Maksymowych WP; Bell NR; Juby AG; Majumdar SR
    Osteoporos Int; 2011 Mar; 22(3):983-91. PubMed ID: 21052642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral bisphosphonate prescription and non-adherence at 12 months in patients with hip fractures treated in an acute geriatric unit.
    Gamboa A; Duaso E; Marimón P; Sandiumenge M; Escalante E; Lumbreras C; Tarrida A
    Osteoporos Int; 2018 Oct; 29(10):2309-2314. PubMed ID: 30076454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates and mortality: confounding in observational studies?
    Bergman J; Nordström A; Hommel A; Kivipelto M; Nordström P
    Osteoporos Int; 2019 Oct; 30(10):1973-1982. PubMed ID: 31367949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005088. PubMed ID: 27760454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Osteoporosis Medications Associated with Decreased Mortality after Hip Fracture.
    Wang PW; Li YZ; Zhuang HF; Yu HM; Cai SQ; Xu H; Chen ZH; Lin JK; Yao XD
    Orthop Surg; 2019 Oct; 11(5):777-783. PubMed ID: 31429532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study.
    Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
    Osteoporos Int; 2016 Jan; 27(1):387-96. PubMed ID: 26576544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients-a nationwide register-based open cohort study.
    Bondo L; Eiken P; Abrahamsen B
    Osteoporos Int; 2013 Jan; 24(1):245-52. PubMed ID: 22638712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of osteoporosis medications for preventing periprosthetic fractures following femoral neck fracture indicated hip arthroplasty: a break-even analysis.
    Agarwal AR; Kinnard MJ; Murdock C; Zhao AY; Ahiarakwe U; Cohen JS; Moseley KF; Golladay GJ; Thakkar SC
    Osteoporos Int; 2024 Jul; 35(7):1223-1229. PubMed ID: 38619605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk.
    Nayak S; Greenspan SL
    Osteoporos Int; 2019 Apr; 30(4):705-720. PubMed ID: 30623214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study.
    Gonnelli S; Caffarelli C; Letizia Mauro G; Di Munno O; Malavolta N; Migliaccio S; Nuti R
    Aging Clin Exp Res; 2019 Nov; 31(11):1541-1547. PubMed ID: 31030419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.
    Imaz I; Zegarra P; González-Enríquez J; Rubio B; Alcazar R; Amate JM
    Osteoporos Int; 2010 Nov; 21(11):1943-51. PubMed ID: 19967338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic.
    Craig SJ; Youssef PP; Vaile JH; Sullivan L; Bleasel JF
    Intern Med J; 2011 Feb; 41(2):186-90. PubMed ID: 20214696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases.
    Olsen KR; Hansen C; Abrahamsen B
    Osteoporos Int; 2013 Oct; 24(10):2639-47. PubMed ID: 23604250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study.
    Sambrook PN; Cameron ID; Chen JS; March LM; Simpson JM; Cumming RG; Seibel MJ
    Osteoporos Int; 2011 Sep; 22(9):2551-6. PubMed ID: 20959963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nurse case-manager vs multifaceted intervention to improve quality of osteoporosis care after wrist fracture: randomized controlled pilot study.
    Majumdar SR; Johnson JA; Bellerose D; McAlister FA; Russell AS; Hanley DA; Garg S; Lier DA; Maksymowych WP; Morrish DW; Rowe BH
    Osteoporos Int; 2011 Jan; 22(1):223-30. PubMed ID: 20358359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
    Rietbrock S; Olson M; van Staa TP
    QJM; 2009 Jan; 102(1):35-42. PubMed ID: 18842684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996-2012: An Ecological Analysis.
    Jha S; Wang Z; Laucis N; Bhattacharyya T
    J Bone Miner Res; 2015 Dec; 30(12):2179-87. PubMed ID: 26018247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced mortality and subsequent fracture risk associated with oral bisphosphonate recommendation in a fracture liaison service setting: A prospective cohort study.
    van Geel TACM; Bliuc D; Geusens PPM; Center JR; Dinant GJ; Tran T; van den Bergh JPW; McLellan AR; Eisman JA
    PLoS One; 2018; 13(6):e0198006. PubMed ID: 29856795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
    Epstein S; Jeglitsch M; McCloskey E
    Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.